Authors (Ref) | Publication year | Sample size (control/intervention) | Country/population | Intervention (name and daily dose) | Duration | Age (control, intervention) | Presented data |
---|---|---|---|---|---|---|---|
Belardinelli et al. [23] | 2006 | 21/21 | Italy/chronic HF | CoQ10 100 mg/day | 4 weeks | 60 ± 8 | TC, LDL-C, TG, HDL-C |
Dai Y et al. [24] | 2011 | 28/28 | Hong Kong/left ventricular systolic dysfunction | CoQ10 300 mg/ day | 8 weeks | 65.9 ± 12.5, 59.9 ± 13.1 | TC, LDL-C, HDL-C, Lp(a) |
Mohseni et al. [15] | 2015 | 26/26 | Iran/acute myocardial infarction | CoQ10 200 mg/day | 12 weeks | 48.4 ± 0.5, 47.6 ± 0.3 | TC, LDL-C, TG, HDL-C |
Mirhashemi et al. [25] | 2016 | 30/30 | Iran/T2DM with CAD | CoQ10 100 mg/day | 8 weeks | 68.9 ± 9.6 | Lp(a) |
Pourmoghaddas M et al. [26] | 2013 | 30/32 | Iran/statin treated coronary heart failure patients | CoQ10 200 mg/ day | 16 weeks | 48.0 ± 8.6, 47.6 ± 8.2 | TC, LDL-C |
Singh et al. [19] | 1999 | 22/25 | India/CAD | CoQ10 120 mg/day | 4 weeks | 50.70 ± 12.5, 54.47 ± 14.6 | TC, LDL-C, HDL-C, Lp(a) |
Singh et al. [14] | 2003 | 71/73 | India/myocardial infarction | CoQ10 120 mg/day | 48 weeks | 51 ± 9, 51 ± 10 | TC, LDL-C, TG, HDL-C |
Sharifi et al. [13] | 2017 | 31/32 | Iran/myocardial infarction | CoQ10 150 mg/day and L-carnitine 1200 mg/day | 3 months | 59 ± 9 | TC |